{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:44:45Z","timestamp":1793810685645,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Boehringer Ingelheim"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03656-y","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:05:59Z","timestamp":1759165559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease"],"prefix":"10.1186","volume":"27","author":[{"given":"Bo","family":"Broens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conny J.","family":"van der Laken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris A.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Willem","family":"Duitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre E.","family":"Voskuyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"10373","key":"3656_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2023","unstructured":"Volkmann ER, Andr\u00e9asson K, Smith V. Systemic sclerosis. Lancet. 2023;401(10373):304\u201318.","journal-title":"Lancet"},{"issue":"11","key":"3656_CR2","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/european league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747\u201355.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3656_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2397198320915042","volume":"6","author":"ER Volkmann","year":"2021","unstructured":"Volkmann ER, Fischer A. Update on morbidity and mortality in systemic sclerosis\u2013related interstitial lung disease. J Scleroderma Relat Disorders. 2021;6(1):11\u201320.","journal-title":"J Scleroderma Relat Disorders"},{"issue":"2","key":"3656_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","volume":"80","author":"AM Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Air\u00f3 P, Ananieva LP, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80(2):219\u201327.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3656_CR5","doi-asserted-by":"publisher","first-page":"102978","DOI":"10.1016\/j.autrev.2021.102978","volume":"20","author":"MC Vonk","year":"2021","unstructured":"Vonk MC, Smith V, Sfikakis PP, Cutolo M, del Galdo F, Seibold JR. Pharmacological treatments for SSc-ILD: systematic review and critical appraisal of the evidence. Autoimmun Rev. 2021;20(12):102978.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"3656_CR6","doi-asserted-by":"publisher","first-page":"e005086","DOI":"10.1136\/rmdopen-2024-005086","volume":"11","author":"Y Allanore","year":"2025","unstructured":"Allanore Y, Vonk MC, Distler O, Azuma A, Mayes MD, James A, et al. Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON. RMD Open. 2025;11(1):e005086.","journal-title":"RMD Open"},{"issue":"9","key":"3656_CR7","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/rheumatology\/kez230","volume":"58","author":"O Bonhomme","year":"2019","unstructured":"Bonhomme O, Andr\u00e9 B, Gester F, de Seny D, Moermans C, Struman I, et al. Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature. Rheumatology (Oxford). 2019;58(9):1534\u201346.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3656_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","volume":"201","author":"D Khanna","year":"2020","unstructured":"Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J, Etiology. Risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med. 2020;201(6):650\u201360.","journal-title":"Am J Respir Crit Care Med"},{"key":"3656_CR9","doi-asserted-by":"crossref","unstructured":"Lavis P, Garabet A, Cardozo AK, Bondue B. The fibroblast activation protein alpha as a biomarker of pulmonary fibrosis. Front Med. 2024;11.","DOI":"10.3389\/fmed.2024.1393778"},{"issue":"13","key":"3656_CR10","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1007\/s00259-021-05475-0","volume":"48","author":"M Sollini","year":"2021","unstructured":"Sollini M, Kirienko M, Gelardi F, Fiz F, Gozzi N, Chiti A. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(13):4396\u2013414.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"51","key":"3656_CR11","doi-asserted-by":"publisher","first-page":"36505","DOI":"10.1074\/jbc.274.51.36505","volume":"274","author":"JE Park","year":"1999","unstructured":"Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity Serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 1999;274(51):36505\u201312.","journal-title":"J Biol Chem"},{"key":"3656_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2741\/4706","volume":"24","author":"AJ Lay","year":"2019","unstructured":"Lay AJ, Zhang HE, McCaughan GW, Gorrell MD. Fibroblast activation protein in liver fibrosis. Front Bioscience (Landmark edition). 2019;24:1\u201317.","journal-title":"Front Bioscience (Landmark edition)"},{"issue":"3","key":"3656_CR13","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","volume":"39","author":"AA Fitzgerald","year":"2020","unstructured":"Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39(3):783\u2013803.","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"3656_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.humpath.2005.11.020","volume":"37","author":"PS Acharya","year":"2006","unstructured":"Acharya PS, Zukas A, Chandan V, Katzenstein AL, Pur\u00e9 E. Fibroblast activation protein: a Serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol. 2006;37(3):352\u201360.","journal-title":"Hum Pathol"},{"issue":"15","key":"3656_CR15","doi-asserted-by":"publisher","first-page":"8070","DOI":"10.1074\/jbc.M115.701433","volume":"291","author":"MH Fan","year":"2016","unstructured":"Fan MH, Zhu Q, Li HH, Ra HJ, Majumdar S, Gulick DL, et al. Fibroblast activation protein (FAP) accelerates collagen degradation and clearance from lungs in mice. J Biol Chem. 2016;291(15):8070\u201389.","journal-title":"J Biol Chem"},{"key":"3656_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejphar.2017.05.022","volume":"809","author":"C Egger","year":"2017","unstructured":"Egger C, Cannet C, G\u00e9rard C, Suply T, Ksiazek I, Jarman E, et al. Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis. Eur J Pharmacol. 2017;809:64\u201372.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"3656_CR17","doi-asserted-by":"publisher","first-page":"L271","DOI":"10.1152\/ajplung.00071.2019","volume":"317","author":"T Kimura","year":"2019","unstructured":"Kimura T, Monslow J, Klampatsa A, Leibowitz M, Sun J, Liousia M, et al. Loss of cells expressing fibroblast activation protein has variable effects in models of TGF-\u03b2 and chronic bleomycin-induced fibrosis. Am J Physiol Lung Cell Mol Physiol. 2019;317(2):L271\u201382.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"3656_CR18","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30421-5","volume":"3","author":"C Bergmann","year":"2021","unstructured":"Bergmann C, Distler JHW, Treutlein C, Tascilar K, M\u00fcller A-T, Atzinger A, et al. 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. Lancet Rheumatol. 2021;3(3):e185\u201394.","journal-title":"Lancet Rheumatol"},{"key":"3656_CR19","doi-asserted-by":"crossref","unstructured":"Corsi F, Sorrentino L, Albasini S, Colombo F, Cigognini M, Massari A et al. Circulating fibroblast activation protein as potential biomarker in patients with inflammatory bowel disease. Front Med. 2021;8.","DOI":"10.3389\/fmed.2021.725726"},{"issue":"4","key":"3656_CR20","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1016\/j.ijcard.2013.06.061","volume":"168","author":"J Tillmanns","year":"2013","unstructured":"Tillmanns J, Widera C, Habbaba Y, Galuppo P, Kempf T, Wollert KC, et al. Circulating concentrations of fibroblast activation protein \u03b1 in apparently healthy individuals and patients with acute coronary syndrome as assessed by sandwich ELISA. Int J Cardiol. 2013;168(4):3926\u201331.","journal-title":"Int J Cardiol"},{"issue":"6","key":"3656_CR21","doi-asserted-by":"publisher","first-page":"e0178987","DOI":"10.1371\/journal.pone.0178987","volume":"12","author":"S Uitte de Willige","year":"2017","unstructured":"Uitte de Willige S, Keane FM, Bowen DG, Malfliet J, Zhang HE, Maneck B, et al. Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease. PLoS ONE. 2017;12(6):e0178987.","journal-title":"PLoS ONE"},{"issue":"11","key":"3656_CR22","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1111\/1756-185X.13031","volume":"21","author":"P Sinnathurai","year":"2018","unstructured":"Sinnathurai P, Lau W, Vieira de Ribeiro AJ, Bachovchin WW, Englert H, Howe G, et al. Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis. Int J Rheum Dis. 2018;21(11):1915\u201323.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"3656_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00296-023-05499-9","volume":"44","author":"J Kosa\u0142ka-W\u0119giel","year":"2024","unstructured":"Kosa\u0142ka-W\u0119giel J, Licho\u0142ai S, Pacholczak-Madej R, Dziedzina S, Milewski M, Kuszmiersz P, et al. Serum IL-17 and TNF\u03b1 as prognostic biomarkers in systemic sclerosis patients: a prospective study. Rheumatol Int. 2024;44(1):119\u201328.","journal-title":"Rheumatol Int"},{"issue":"2","key":"3656_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/rheumatology\/ket331","volume":"53","author":"G Ruiter","year":"2013","unstructured":"Ruiter G, Lanser IJ, de Man FS, van der Laarse WJ, Wharton J, Wilkins MR, et al. Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology. 2013;53(2):285\u201392.","journal-title":"Rheumatology"},{"issue":"12","key":"3656_CR25","doi-asserted-by":"publisher","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","volume":"3","author":"S Bellando-Randone","year":"2021","unstructured":"Bellando-Randone S, Del Galdo F, Lepri G, Minier T, Huscher D, Furst DE, et al. Progression of patients with raynaud\u2019s phenomenon to systemic sclerosis: a five-year analysis of the European scleroderma trial and research group multicentre, longitudinal registry study for very early diagnosis of systemic sclerosis (VEDOSS). Lancet Rheumatol. 2021;3(12):e834\u201343.","journal-title":"Lancet Rheumatol"},{"key":"3656_CR26","doi-asserted-by":"publisher","first-page":"e47969","DOI":"10.7554\/eLife.47969","volume":"8","author":"A Sinha","year":"2019","unstructured":"Sinha A, Lutter R, Xu B, Dekker T, Dierdorp B, Sterk PJ, et al. Loss of adaptive capacity in asthmatic patients revealed by biomarker fluctuation dynamics after rhinovirus challenge. eLife. 2019;8:e47969.","journal-title":"eLife"},{"issue":"Suppl 1","key":"3656_CR27","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1136\/annrheumdis-2023-eular.3181","volume":"82","author":"AM Hoffmann-Vold","year":"2023","unstructured":"Hoffmann-Vold AM, Petelytska L, Fretheim H, Barua I, Becker MO, Bj\u00f8rkekj\u00e6r HJ, et al. POS1291\u2005Prediction of mortality in SSC-ILD depends on definition of ILD progression. Ann Rheum Dis. 2023;82(Suppl 1):992\u20133.","journal-title":"Ann Rheum Dis"},{"key":"3656_CR28","unstructured":"Matteson EL, Kelly C, Distler JHW, Hoffmann-Vold A-M, Seibold JR, Mittoo S et al. Nintedanib in Patients With Autoimmune Disease\u2013Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial. Arthritis & Rheumatology.n\/a(n\/a)."},{"issue":"9","key":"3656_CR29","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"key":"3656_CR30","doi-asserted-by":"crossref","unstructured":"Dorst DN, van Caam APM, Vitters EL, Walgreen B, Helsen MMA, Klein C et al. Fibroblast activation protein targeted photodynamic therapy selectively kills activated skin fibroblasts from systemic sclerosis patients and prevents tissue contraction. Int J Mol Sci. 2021;22(23).","DOI":"10.3390\/ijms222312681"},{"issue":"8","key":"3656_CR31","doi-asserted-by":"publisher","first-page":"e12476","DOI":"10.15252\/emmm.202012476","volume":"12","author":"EL Nirk","year":"2020","unstructured":"Nirk EL, Reggiori F, Mauthe M. Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med. 2020;12(8):e12476.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"3656_CR32","doi-asserted-by":"publisher","first-page":"e13392","DOI":"10.1111\/sji.13392","volume":"100","author":"TS Prior","year":"2024","unstructured":"Prior TS, Hoyer N, Davidsen JR, Shaker SB, Hundahl MP, Lomholt S, et al. Fibroblast activation protein and disease severity, progression, and survival in idiopathic pulmonary fibrosis. Scand J Immunol. 2024;100(3):e13392.","journal-title":"Scand J Immunol"},{"issue":"supplement 1","key":"3656_CR33","first-page":"298","volume":"60","author":"M R\u00f6hrich","year":"2019","unstructured":"R\u00f6hrich M, Leitz D, Flechsig P, Kahn N, Mall M, Michael K, et al. Fibroblast activation Protein - specific PET\/CT imaging in idiopathic pulmonary fibrosis with lung cancer. J Nucl Med. 2019;60(supplement 1):298.","journal-title":"J Nucl Med"},{"issue":"2","key":"3656_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1164\/rccm.202110-2414OC","volume":"207","author":"P Yang","year":"2023","unstructured":"Yang P, Luo Q, Wang X, Fang Q, Fu Z, Li J, et al. Comprehensive analysis of fibroblast activation protein expression in interstitial lung diseases. Am J Respir Crit Care Med. 2023;207(2):160\u201372.","journal-title":"Am J Respir Crit Care Med"},{"key":"3656_CR35","doi-asserted-by":"publisher","first-page":"132044","DOI":"10.1016\/j.ijcard.2024.132044","volume":"406","author":"J Tillmanns","year":"2024","unstructured":"Tillmanns J, Weiglein JM, Neuser J, Fraccarollo D, Galuppo P, K\u00f6nig T, et al. Circulating soluble fibroblast activation protein (FAP) levels are independent of cardiac and extra-cardiac FAP expression determined by targeted molecular imaging in patients with myocardial FAP activation. Int J Cardiol. 2024;406:132044.","journal-title":"Int J Cardiol"},{"key":"3656_CR36","doi-asserted-by":"crossref","unstructured":"Petelytska L, Bonomi F, Cannistr\u00e0 C, Fiorentini E, Peretti S, Torracchi S et al. Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review. RMD Open. 2023;9(4).","DOI":"10.1136\/rmdopen-2023-003426"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03656-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03656-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03656-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:06:04Z","timestamp":1759165564000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03656-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3656"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03656-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The medical ethics committee of the Amsterdam UMC, location VUmc and AMC, approved the study. All patients and controls have provided oral and written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}